SAN DIEGO--(BUSINESS WIRE)--CryoPort, Inc. (OTCBB: CYRX) was mentioned in a 60 MINUTES story Sunday night as the “highest medical standard” for safely and securely transporting cryogenically frozen materials. The CryoPort solution was used to transport stem cells to Duke University for testing. It was the combination of dry shipper technology and data monitoring that allowed the Duke University team and 60 MINUTES to prove stem cell specimen viability.
“We were pleased to be recognized as the highest medical standard in the industry,” said Larry Stambaugh, CryoPort’s chairman and chief executive officer. “Our proven deep frozen technology is the ideal logistics solution for life science companies worldwide.”
Watch the video and the CryoPort dry shipper shown at minute 7:13: 60 Minute Stem Cell video
About CryoPort, Inc.
CryoPort provides leading edge cold chain logistics services through the combination of purpose built proprietary technologies and total turnkey management of the entire process. The CryoPort Express liquid nitrogen based dry vapor shipper is validated to maintain a constant -150°C temperature for a minimum 10-day dynamic shipment duration, and its CryoPortal Logistics Management Platform manages the entire shipment process, including initial order, document preparation, customs clearance, courier management, shipment tracking, issue resolution,and delivery. CryoPort’s total turnkey service management approach offers reliability, cost effectiveness, and convenience, while the use of recyclable and reuseable components provides a “green” and environmentally friendly solution. For more information visit www.cryoport.com and the Cold Chain Transport blog at http://www.cryoport.com/biological-shipping-blog/.
Forward Looking Statements
Statements in this press release which are not purely historical, including statements regarding CryoPort, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2011. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. CryoPort, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.